International Patent: SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS

GENEVA, July 18 -- JANSSEN PHARMACEUTICA NV filed a patent application (EP2026/050139) for “SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS”. With publication no. WO/2026/149913, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61P 35/00

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....